Daniel Lysak

Dr. Daniel Lysak

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2012 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
HKHagop M. Kantarjian
Hagop M. Kantarjian
XTXavier G. Thomas
Xavier G. Thomas
ADAnna Dmoszynska
Anna Dmoszynska
AWAgnieszka Wierzbowska
Agnieszka Wierzbowska
GMGrzegorz Mazur
Grzegorz Mazur
CAChristopher Arthur
Christopher Arthur
Purpose: This multicenter, randomized, open-label, phase III trial compared the efficacy and safety of decitabine with treatment choice (TC) in older patients with newly diagnosed acute myeloid leukemia (AML) and poor- or intermediate-risk cytogenetics. Patients and Methods: Patients (N = 485) age ≥ 65 years were randomly assigned 1:1 to receive decitabine 20 mg/m2 per day as a 1-hour intravenous infusion for five consecutive days every 4 weeks or TC (supportive care or cytarabine 20 mg/m2 per day as a subcutaneous injection for 10 consecutive days every 4 weeks). The primary end point was overall survival (OS); the secondary end point was the complete remission (CR) rate plus the CR rate without platelet recovery (CRp). Adverse events (AEs) were recorded. Results: The primary analysis with 396 deaths (81.6%) showed a nonsignificant increase in median OS with decitabine (7.7 months; 95% CI, 6.2 to 9.2) versus TC (5.0 months; 95% CI, 4.3 to 6.3; P = .108; hazard ratio [HR], 0.85; 95% CI, 0.69 to 1.04). An unplanned analysis with 446 deaths (92%) indicated the same median OS (HR, 0.82; 95% CI, 0.68 to 0.99; nominal P = .037). The CR rate plus CRp was 17.8% with decitabine versus 7.8% with TC (odds ratio, 2.5; 95% CI, 1.4 to 4.8; P = .001). AEs were similar for decitabine and cytarabine, although patients received a median of four cycles of decitabine versus two cycles of TC. The most common drug-related AEs with decitabine were thrombocytopenia (27%) and neutropenia (24%). Conclusion: In older patients with AML, decitabine improved response rates compared with standard therapies without major differences in safety. An unplanned survival analysis showed a benefit for decitabine, which was not observed at the time of the primary analysis.

5 October 2010 in Proteomics – Clinical Applications
Verified
Journal Article
Closed access
PDF file
JMJan Mares
Jan Mares
PRPavlina Richtrova
Pavlina Richtrova
AHAlena Hricinova
Alena Hricinova
ZTZdenek Tuma
Zdenek Tuma
JMJiri Moravec
Jiri Moravec
MMMartin Matejovic
Martin Matejovic

1 November 2005 in Transfusion and Apheresis Science
Verified
Journal Article
Closed access
DLDaniel Lysak
Daniel Lysak
VKVladimír Koza
Vladimír Koza
PJPavel Jindra
Pavel Jindra

1 February 2015 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
TRTomas Reischig
Tomas Reischig
MKMartin Kacer
Martin Kacer
PJPavel Jindra
Pavel Jindra
OHOndrej Hes
Ondrej Hes
DLDaniel Lysak
Daniel Lysak
MBMirko Bouda
Mirko Bouda
Background and objectives Both valganciclovir and high-dose valacyclovir are recommended for cytomegalovirus prophylaxis after renal transplantation. A head-to-head comparison of both regimens is lacking. The objective of the study was to compare valacyclovir prophylaxis with valganciclovir, which constituted the control group. Design, settings, participants, & measurements In a randomized, open-label, single-center trial, recipients of renal transplants (recipient or donor cytomegalovirus-seropositive) were randomly allocated (1:1) to 3-month prophylaxis with valacyclovir (2 g four times daily) or valganciclovir (900 mg daily). Enrollment occurred from November of 2007 to April of 2012. The primary end points were cytomegalovirus DNAemia and biopsy-proven acute rejection at 12 months. Analysis was by intention to treat. Results In total, 119 patients were assigned to valacyclovir (n=59) or valganciclovir prophylaxis (n=60). Cytomegalovirus DNAemia developed in 24 (43%) of 59 patients in the valacyclovir group and 18 (31%) of 60 patients in the valganciclovir group (adjusted hazard ratio, 1.35; 95% confidence interval, 0.71 to 2.54; P=0.36). The incidence of cytomegalovirus disease was 2% with valacyclovir and 5% with valganciclovir prophylaxis (adjusted hazard ratio, 0.21; 95% confidence interval, 0.01 to 5.90; P=0.36). Significantly more patients with valacyclovir prophylaxis developed biopsy-proven acute rejection (18 of 59 [31%] versus 10 of 60 [17%]; adjusted hazard ratio, 2.49; 95% confidence interval, 1.09 to 5.65; P=0.03). The incidence of polyomavirus viremia was higher in the valganciclovir group (18% versus 36%; adjusted hazard ratio, 0.43; 95% confidence interval, 0.19 to 0.96; P=0.04). Conclusions Valganciclovir shows no superior efficacy in cytomegalovirus DNAemia prevention compared with valacyclovir prophylaxis. However, the risk of biopsy-proven acute rejection is higher with valacyclovir.

27 October 2010 in Journal of Clinical Apheresis
Verified
Journal Article
Closed access
PDF file
DLDaniel Lysak
Daniel Lysak
ZKZdenek Koristek
Zdenek Koristek
ZGZdeňka Gašová
Zdeňka Gašová
ISIva Skoumalová
Iva Skoumalová
PJPavel Jindra
Pavel Jindra

1 December 2015 in Leukemia Research
Verified
Journal Article
Closed access
LKLinda Koutova
Linda Koutova
MSMonika Sterbova
Monika Sterbova
EPEva Pazourkova
Eva Pazourkova
SPSarka Pospisilova
Sarka Pospisilova
ISIveta Svobodova
Iveta Svobodova
MKMarie Korabecna
Marie Korabecna